Literature DB >> 10884515

Role of nitric oxide in diabetes-induced attenuation of antinociceptive effect of morphine in mice.

V S Grover1, A Sharma, M Singh.   

Abstract

The study was designed to investigate the role of nitric oxide (NO) in the diabetes-induced decrease of the antinociceptive effect of morphine. The nociceptive threshold in diabetic and non-diabetic mice was measured in the tail-flick test. Streptozotocin (200 mg/kg i.p.) was administered to induce experimental diabetes in the mice. Four weeks after the administration of streptozotocin, the tail-flick test was performed and urinary nitrite concentration was estimated using Greiss reagent. Experimental diabetes markedly decreased the antinociceptive effect of morphine (10 microg in 5 microl/mice i.c.v.) and significantly increased the urinary nitrite concentration. Administration of aminoguanidine (12 mg/mice) markedly improved the antinociceptive effect of morphine and attenuated the increase in urinary nitrite concentration in diabetic mice. It may be tentatively concluded that an increase in NO formation may be responsible for the observed decrease in antinociceptive effect of morphine in diabetic mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884515     DOI: 10.1016/s0014-2999(00)00343-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Reversal of diabetic vasculopathy in a rat model of type 1 diabetes by opiorphin-related peptides.

Authors:  Giulia Calenda; Yuehong Tong; Nirmala D Kanika; Moses T Tar; Sylvia O Suadicani; Xinhua Zhang; Arnold Melman; Catherine Rougeot; Kelvin P Davies
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-22       Impact factor: 4.733

2.  Possible mechanism of protective effect of thalidomide in STZ-induced-neuropathic pain behavior in rats.

Authors:  Rajeev Taliyan; Pyare Lal Sharma
Journal:  Inflammopharmacology       Date:  2011-12-17       Impact factor: 4.473

Review 3.  Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Matthew S Klocek; Ian S Zagon
Journal:  Brain Res Bull       Date:  2009-08-14       Impact factor: 4.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.